Bionutrics Announces Issuance of Broad Patent for Use of Tocotrienols Against Cancer.PHOENIX--(BUSINESS WIRE)--July 28, 1999-- Bionutrics Inc. (Nasdaq:BNRX) announced today that it has received a United States patent that broadly covers the use of tocotrienol vitamin E vitamin E or tocopherol Fat-soluble organic compound found principally in certain plant oils and leaves of green vegetables. Vitamin E acts as an antioxidant in body tissues and may prolong life by slowing oxidative destruction of membranes. compounds for treating and preventing cancer. The patent, which was issued on July 6, 1999, as US patent 5,919,818, includes method claims directed to the treatment and prevention of cancer using naturally occurring tocotrienols and certain synthetic tocotrienol analogs. Tocotrienols are the newest members of the vitamin E family and differ from the more common vitamin E tocopherols in their chemical structure. In a further development, Bionutrics has been informed of positive results by the National Cancer Institute ("NCI See Liberate. ") Developmental Therapeutics Program, a division of its Cancer Treatment and Diagnosis group. Two proprietary tocotrienols submitted for testing by Bionutrics' subsidiary LipoGenics Inc. demonstrated activity in the NCI's in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. anticancer activity screen. The screen consists of 60 individual cancer cell lines representing nine general types of cancer. Based on these results, the NCI has scheduled continued investigation. The reported anticancer activity of Bionutrics' tocotrienols complements results recently published in the scientific literature confirming the ability of naturally occurring tocotrienols to inhibit the growth of various cancer cell lines in culture, including several types of human breast cancer. Bionutrics Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Ronald H. Lane, Ph.D., commented, "We are very excited about the issuance of this patent and the positive results our tocotrienol compounds displayed in the NCI anticancer screen. These developments place Bionutrics in an ideal position to advance our technology platform towards therapeutic applications of tocotrienols in the cancer field. This opportunity allows us to build on the solid foundation we have already established for the nutritional use of tocotrienols in promoting cardiovascular health." Bionutrics is an emerging biopharmaceutical company founded to discover and develop novel biologically active compounds derived from natural sources. Natural, biologically active compounds have potential applications as ethical drugs as well as functional nutrition ingredients. Bionutrics introduced its first tocotrienol-based product, evolvE(R) Advanced Cardiovascular Dietary Supplement, and is presently developing additional proprietary functional nutrition ingredients with applications beyond cardiovascular health. The Bionutrics Board of Directors, in addition to Dr. Lane, includes: C. Everett Koop Charles Everett Koop, (born October 14 1916 in Brooklyn, New York) is an American physician. He served as the Surgeon General of the United States from 1982 to 1989, under Ronald Reagan's presidency. , M.D., former Surgeon General of the United States; Daniel Antonelli, CEO of AC Humko Corp.; Winston Salser, Ph.D., professor of Molecular Biology at UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX and founding president of Amgen Inc.; Frederick B. Rentschler, chairman of the Salk Institute and former president and CEO of Beatrice Foods; William M. McCormick, vice chairman of Bionutrics Inc., former president of American Express Travel Related Services Company and former CEO of Fireman's Fund and Penn Corp.; Steve Henig, Ph.D., senior vice president of Technology and Innovation of Ocean Spray Cranberries Inc.; Milt Okin, creator of Weight Watchers Foods; Richard M. Feldheim, president of Abby's Restaurants and former president of Norcap Financial Corporation; Robert B. Goergen Robert B. Goergen is an American corporate executive, entrepreneur and philanthropist. He is the founder, chairman and CEO of Blyth, Inc. He is also the founder and chairman of The Ropart Group, a private-equity investment firm. , chairman and CEO of Blyth Industries and chairman of XTRA XTRA Extra XTRA X-band Thin Radar Aperture (US DoD) XTRA Xml Transaction Architecture Corporation, NYSE NYSE See: New York Stock Exchange companies; and Donald A. Winkler Winkler may refer to:
"Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains forward-looking statements that are subject to risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment and governmental approval processes, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion